Get the Stockscreener App
5.74
10.59%
-0.68
Passage Bio Inc stock is traded at $5.74, with a volume of 48,926.
It is down -10.59% in the last 24 hours and up +1,410% over the past month.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
See More
Previous Close:
$6.42
Open:
$6.29
24h Volume:
48,926
Relative Volume:
0.15
Market Cap:
$17.91M
Revenue:
-
Net Income/Loss:
$-68.80M
P/E Ratio:
-4.906
EPS:
-1.17
Net Cash Flow:
$-59.06M
1W Performance:
-22.85%
1M Performance:
+1,410%
6M Performance:
+882.88%
1Y Performance:
+504.85%
1-Day Range:
$5.60
$6.3495
1-Week Range:
$5.60
$7.566
52-Week Range:
$0.257
$7.6996
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
5.74 | 20.03M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Real time social sentiment graph for Passage Bio Inc.Daily Profit Watch With Forecast Confidence - Newser
Technical signs of recovery in Passage Bio Inc.RSI and MACD Signal Summary with Trends - Newser
Why Passage Bio Inc. stock attracts strong analyst attentionSector Rotation and Stock Opportunity Analysis - Newser
Is Passage Bio Inc. a candidate for recovery playFree Day Trading Signals With High Precision - Newser
Will Passage Bio Inc. Stock Benefit from AI and Green Energy TrendsAI Risk Optimized Trade Forecast Planner - Newser
What analysts say about Passage Bio Inc. stock outlookReal-Time Setup Summary with ROI Focus - Newser
Is Passage Bio Inc. a growth stock or a value stockStock Market Entry Points To Watch Now - jammulinksnews.com
What moving averages say about Passage Bio Inc.Market Ready Picks with Technical Support - Newser
Historical volatility pattern of Passage Bio Inc. visualizedSmart Entry Signals for Active Traders - Newser
Is Passage Bio Inc. Stock a Good Fit for Conservative InvestorsCommunity Picked Stocks with Trade Insights - Newser
How many analysts rate Passage Bio Inc. as a “Buy”Beginner Investor Planner With Low Risk - jammulinksnews.com
Passage Bio Regains Nasdaq Compliance with Stock Price - The Globe and Mail
Passage Bio Inc. Shows Early Signs of Technical StrengthHigh Win Rate Trading Opportunities Detected - metal.it
How strong is Passage Bio Inc. company’s balance sheetRetirement Planning Forecasts For Consistent Profits - jammulinksnews.com
What machine learning models say about Passage Bio Inc.Forecasting Stock Moves with AI Insights - Newser
What moving averages say about Passage Bio Inc. Weekly Breakout Forecast with Entry Zones - Newser
What machine learning models say about Passage Bio Inc. Accurate Forecast System with AI Support - Newser
Does Passage Bio Inc. stock perform well during market downturnsExplosive trading opportunities - jammulinksnews.com
What is the dividend policy of Passage Bio Inc. stockMarket-beating performance - jammulinksnews.com
What are Passage Bio Inc. company’s key revenue driversBuild a diversified portfolio for risk management - jammulinksnews.com
What are the latest earnings results for Passage Bio Inc.Superior trading gains - jammulinksnews.com
What are analysts’ price targets for Passage Bio Inc. in the next 12 monthsDiscover breakthrough stocks with expert help - jammulinksnews.com
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):